ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
13 hedge funds and large institutions have $1.88M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
20% more capital invested
Capital invested by funds: $1.58M → $1.88M (+$309K)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
4.39% less ownership
Funds ownership: 17.97% → 13.58% (-4.4%)
13% less funds holding
Funds holding: 15 → 13 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$253K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$178K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$68.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.3K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$6.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vontobel Holding
Zurich,
Switzerland
|
-$283K |
| 2 |
Jane Street
New York
|
-$151K |
| 3 |
LPL Financial
San Diego,
California
|
-$128K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$113K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$38.1K |
CNCR Hedge Fund Activity: Q4 2023 in Review
13 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2023, worth a combined $1.88M — up 20% from $1.58M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CNCR and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $253K. The largest seller was Vontobel Holding, exiting entirely with an estimated $283K sold.
- 13 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2023, down from 15 in Q3 2023.
- Funds reported $1.88M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2023, up 20% quarter-over-quarter.
- 4 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2023 and 5 closed out, a net change of -1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2023 was Morgan Stanley, an estimated $253K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2023 was Vontobel Holding, an estimated $283K sold.
Based on aggregated 13F filings for Q4 2023.